WO2004017994A1 - 喘息の予防および/または治療剤 - Google Patents
喘息の予防および/または治療剤 Download PDFInfo
- Publication number
- WO2004017994A1 WO2004017994A1 PCT/IB2003/003470 IB0303470W WO2004017994A1 WO 2004017994 A1 WO2004017994 A1 WO 2004017994A1 IB 0303470 W IB0303470 W IB 0303470W WO 2004017994 A1 WO2004017994 A1 WO 2004017994A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- compound
- unsubstituted
- seq
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to a prophylactic or therapeutic agent for asthma, which comprises, as an active ingredient, a substance that suppresses the function related to GPR4 signal transduction.
- the present invention also relates to a prophylactic and / or therapeutic agent for asthma containing a nitrogen-containing tricyclic compound or a quaternary ammonium salt thereof or a pharmacologically acceptable salt thereof as an active ingredient.
- Bronchial asthma is an inflammatory disease characterized primarily by airway narrowing and airway hypersensitivity. At present, it is said that daily management of asthma can be sufficiently performed by a combination of inhaled steroids, bronchodilators such as / 3 stimulants ⁇ xanthine, and antiallergic drugs such as antileukotrienes. I have. However, steroid drugs used mainly for treatment have side effects, and some patients have steroid-resistant or intractable patients. Is required.
- GPR4 a G protein-coupled receptor protein (hereinafter abbreviated as GPCR), is known to be highly expressed in the lungs [Genomics (Genomics :), Vol. 30, pp. 84-88 ( 1995)]. GPR4 has also been reported to bind to the lipid sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) and to transmit signals [Journal 'ob' biologic chemistry. Story (J. Biol. Chem.), Vol. 276, 1325-41335 W (2001)]. It has been reported that SPC induces TNF- ⁇ production and ICAM-1 expression [J. Invest.
- SPC lipid sphingosylphosphorylcholine
- LPC lysophosphatidylcholine
- GPCRs known as constitutively active GPCRs which, when overexpressed in cells, cause a signal to flow without the presence of a ligand, are known.
- the signal that flows in the absence of ligand is called constitutive activity.
- Constitutively active GPCRs include naturally occurring ones and mutant GPCRs created by introducing mutations such as amino acid substitutions and deletions [Molecular Pharmacol. ), 57 volumes, 890 pages (2000), W098 / 46995] Antagonists that suppress the constitutive activity of GPCRs are called inverse gonists.
- An object of the present invention is to provide a prophylactic and / or therapeutic agent for asthma containing as an active ingredient a substance that suppresses the function related to GPR4 signal transduction, and to provide a nitrogen-containing tricyclic compound or a quaternary ammonium salt thereof.
- Those drugs An object of the present invention is to provide a preventive and / or therapeutic agent for asthma, which contains a physiologically acceptable salt as an active ingredient.
- the present invention relates to the following (1) to (8).
- a prophylactic and / or therapeutic agent for asthma which comprises, as an active ingredient, a substance that suppresses a signal transmission function of a protein having the amino acid sequence of SEQ ID NO: 11.
- a preventive and / or therapeutic agent for asthma comprising any one of the above as an active ingredient.
- a preventive and / or therapeutic agent for asthma comprising any one of the above as an active ingredient.
- R 1 is a substituted or unsubstituted heterocyclic group, -NR 5 R 6 (wherein R 5 and R 6 are the same or different and are hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted R 5 and R 6 represent substituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl, Together with an adjacent nitrogen atom to form a substituted or unsubstituted heterocyclic group), -OR 7 , wherein R 7 is hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted Lower alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower
- R 2 is hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl Or represents a substituted or unsubstituted heterocyclic alkyl,
- R 3 and are the same or different and each represents hydrogen, lower alkyl, or halogen Represent
- n 0 or 1
- Z 1 and Z 2 are the same or different and are hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted Represents lower alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl, or wherein Z 1 and Z 2 are each one of two adjacent carbon atoms Forming a substituted or unsubstituted aromatic ring or a substituted or unsubstituted heterocyclic ring,
- Z 3 is hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl.
- a prophylactic and / or therapeutic agent for asthma containing a pharmacologically acceptable salt thereof as an active ingredient.
- No Z 1 and Z 2 are placing serial in any one of (4) section, second (7) section to form a 2. one connexion substituted or unsubstituted heterocyclic ring such together with the carbon atom adjacent each An agent for preventing and / or treating asthma.
- the present invention relates to the following (11) to (23).
- n, RR 2 , R 3 , RX and Y are as defined above, or a quaternary ammonium salt thereof, or a pharmaceutically acceptable salt thereof. Salt.
- a method for preventing or treating asthma which comprises administering a therapeutically effective amount of a substance that suppresses a signal transduction function of a protein having the amino acid sequence of SEQ ID NO: 11.
- a method for preventing asthma which comprises administering a therapeutically effective amount of any one of the oligonucleotides or the oligonucleotide derivatives of any one of (1) to (4) described in (2). Yepino or treatment method.
- a method for preventing and / or treating asthma which comprises administering a therapeutically effective amount of the antibody of any one of (1) to (4) according to (3).
- the novel nitrogen-containing tricyclic compound described in (11) to (15) or a quaternary ammonium salt thereof or a pharmaceutically acceptable salt thereof is provided.
- the present inventors have found that a substance that suppresses the function of GPR4, which is a GPCR, related to signal transduction is effective in preventing and / or treating asthma, and has completed the present invention.
- the present inventors searched for a substance that suppresses the constitutive activity of GPR4, which is a constitutively active GPCR, and found that the substance that suppresses the constitutive activity of GPR4 is effective in preventing or treating asthma. Was found to be.
- Examples of the substance that suppresses the signal transduction function of GPR4 include a substance that inhibits or suppresses the expression of GPR4 itself, a substance that inhibits the binding of a ligand to GPR4, and a signal transduction caused by binding of a ligand to GPR4 [for example, Changes in intracellular cAMP concentration (increase or decrease), changes in intracellular Ca 2+ concentration (increase), and suppression of mitogen-activated protein (MAP) kinase substances that suppress signal transduction caused by the constitutive activity of GPR4 (including, for example, the inverse agonist of GPR4).
- the structure of the above substance is not particularly limited as long as it has these functions, and may have a known structure.
- a protein having the amino acid sequence described in any one selected from SEQ ID NOs: 11, 13, and 17, or any one selected from SEQ ID NOs: 11, 13, and 17 Has an amino acid sequence in which at least one amino acid is deleted, substituted or added in the amino acid sequence described in (1), and has a function related to signal transmission of a protein having the amino acid sequence of SEQ ID NO: 11 And proteins.
- SEQ ID NO: 11 has an amino acid sequence in which one or more amino acids are deleted, substituted or added in the amino acid sequence described in any one of SEQ ID NOs: 11, 13 and 17, and SEQ ID NO: 11
- the protein having a function related to signal transduction of a protein having the described amino acid sequence is described in [Molecular Cloning, A
- the number of amino acids deleted, substituted or added is not particularly limited, but is preferably 1 to several tens, preferably 1 to 20, more preferably 1 to 10, and more preferably:! ⁇ 5.
- Deletion, substitution, or addition of one or more amino acid residues in the amino acid sequence according to any one of SEQ ID NOs: 11, 13, and 17 means that any amino acid residue in the amino acid sequence And one or more amino acid residues are deleted, substituted or added at one or more positions, and the deletion, substitution or addition may occur simultaneously,
- the amino acid residue to be substituted or added may be either natural or non-natural.
- Natural amino acid residues include L-alanine, L-asparagine, L-asparaginic acid, L-glutamine, L-glutamic acid, glycine, L-histidine, L-isoleucine, L-leucine, L- -Lysine, L-arginine, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valin and L- Each residue of cystine and the like can be mentioned.
- Group A leucine, isoleucine, nonorleucine, norin, nonolein / lin, lanin, 2-aminobutanoic acid, methionine, 0-methinoreserin, tert-ptinoregulin, tert-ptinolelanine, cyclohexinoleranine
- Group B Aspartic acid, glutamic acid, isoaspartic acid, isoglutamic acid, 2-aminoadipic acid, 2-aminosperic acid
- Group D lysine, arginine, ordinine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid
- Group E Proline, 3-hydroxyproline, 4-hydroxyproline
- Group F serine, threonine, homoserine
- Group G pheninoleanine, tyrosine
- a protein having an amino acid sequence in which one or more amino acid residues are deleted, substituted or added in the amino acid sequence according to any one of SEQ ID NOs: 11, 13, and 17, In order to have a function relating to signal transduction of a protein having the amino acid sequence of SEQ ID NO: 11, the amino acid sequence of the protein and the amino acid sequence of SEQ ID NO: 11 must be at least 75% or more, usually at least 80%. Above, it is preferable that they have 90% or more, more preferably 95% or more identity.
- Substances that inhibit or suppress the expression of GPR itself include, for example, SEQ ID NO:
- Oligonucleotides having a complementary sequence of 15 to 60 consecutive nucleotides selected from the nucleotide sequence of any one selected from 12, 14, and 18 (hereinafter referred to as anti- DNA sequence having the nucleotide sequence of any one selected from SEQ ID NOS: 12, 14, and 18; and Function related to signal transduction of protein having amino acid sequence of SEQ ID NO: 11 And oligonucleotide derivatives thereof (hereinafter, referred to as oligonucleotide derivatives), and the like.
- the antisense oligonucleotide is an oligonucleotide consisting of 15 to 60 consecutive nucleotides selected from the nucleotide sequence of any one selected from SEQ ID NOS: 12, 14, and 18. It is not particularly limited as long as it is an antisense oligonucleotide having a complementary sequence of a gonucleotide, but is preferably 17 to 60 bases, more preferably 20 to 60 bases, and furthermore, Antisense oligonucleotides having an complementary sequence of oligonucleotides preferably consisting of 30 to 60 bases are exemplified.
- an antisense 'oligonucleotide having the complementary sequence of the translation initiation region of the above-mentioned oligonucleotide.
- the antisense oligonucleotide is prepared by a conventional method based on the information on the nucleotide sequence of any one selected from SEQ ID NOs: 12, 14, and 18 or the nucleotide sequence of a fragment thereof. For example, it can be prepared by using a DNA synthesizer.
- Oligonucleotide derivatives include an oligonucleotide derivative in which the phosphoric acid ester bond in the oligonucleotide is converted to a phosphorothioate bond, and a diesterol phosphate bond in the oligonucleotide are ⁇ 3'-.
- Oligonucleotide derivative converted to P5 'phosphoamide bond Oligonucleotide derivative, Oligonucleotide in which the bond between ribose and phosphate diester in the oligonucleotide is converted to peptide nucleic acid bond
- Oligonucleotide derivatives in which peracyl in the oligonucleotide is substituted with C-5 propynyl peracyl Oligonucleotide derivatives in which peracyl in the oligonucleotide is substituted with C-5 thiazolyl peracyl, derivatives in oligonucleotide
- Nucleotides that hybridize under stringent conditions with DNA having the base sequence described in any one selected from SEQ ID NOs: 12, 14, and 18 include SEQ ID NOS: 12, 1 A part or all of the DNA having the nucleotide sequence described in any one of 4 and 18 is used as a probe, and the colony is hybridized, plaque hybridized, Southern blot hybridized, and Southern blot hybridized. Means MA obtained by using the method, etc.
- a 0.1 to 2 times concentration of SSC solution include a DNA or the like that can be identified Ri by the by washing the filters with 6 5 ° C conditions.
- Hypri-dailyization is based on the first edition of Morexura's Cloning, the current version of Protoconorez, the second edition of Molecular / Diology, DNA Clonin 1: Core Techniques, A Practical Approach, Second Edition, Oxford University (1995 ) Etc. It can be carried out according to the method described here. Nucleotides to be hybridized include, for example, 12, 14, and 18 force when calculated using BLAST, FASTA, and the like.
- DNA having a homology of at least 75% or more to the DNA having a complementary sequence of the DNA having the base sequence described in any one selected from the group consisting of the nucleotides described above, and more preferably 80% or more DNA having homology of more than 95%, more preferably DNA having homology of 95% or more.
- the nucleotide a DNA which can be used for both DNA and RNA is preferably used.
- antisense 'oligonucleotide or the antisense' oligonucleotide derivative, or a DNA having the base sequence of any one selected from SEQ ID NOS: 12, 14, and 18 and a string.
- Nucleotides or nucleotide derivatives that hybridize under transient conditions alone or after introduction into a vector for gene therapy such as a retrovirus vector, adenovirus vector, adenovirus associated virus vector, etc. It can be used as a prophylactic and / or therapeutic agent for asthma prepared in accordance with the conventional method.
- a gene therapy vector When a gene therapy vector is used as the prophylactic or therapeutic agent, it can be produced by combining the gene therapy vector and the base used for the gene therapy agent [Nature Genet. , 8, 42 (1994)].
- the above-mentioned base may be any base that is usually used for injections, for example, distilled water, sodium chloride or a salt solution such as a mixture of sodium chloride and an inorganic salt, or the like.
- examples thereof include sugar solutions such as mannitol, lactose, dextran and pudose, amino acid solutions such as glycine and arginine, and mixed solutions of an organic acid solution or a salt solution and a dalcose solution.
- an osmotic pressure adjusting agent a pH adjusting agent, a vegetable oil such as sesame oil and soybean oil, or an auxiliary agent such as lecithin or a surfactant such as a nonionic surfactant is added to these bases,
- the injection may be prepared as a solution, suspension or dispersion. These injections can also be prepared as preparations for dissolution at the time of use by operations such as powdering and freeze-drying.
- the prophylactic and / or therapeutic agent can be used as it is in the case of a liquid, or in the case of a solid, immediately before administration, if necessary, dissolved in the above-mentioned sterilized base.
- Examples of the administration method include a method of local administration so that it is absorbed at the treatment site of the patient.
- non-viral gene transfer DNA can be transported to the target treatment site.
- Non-viral gene transfer methods include calcium phosphate coprecipitation [Virology, 52, 456-467 (1973); Science, 209, 1414-1422 (1980)], and microinjection [Proc. Natl. Acad. Sci. USA, 77. 5399-5403 (1980); Proc. Natl. Acad. Sci. USA, T_, 7380-7384 (1980); Cell, 27, 223-231 (1981); Nature, 294, 92-94 (1981)], liposome-mediated membrane fusion-mediated transfer method [Proc. Natl. Acad. Sci. USA, 84, 7413-7417 (1987); Biochemistry, 28, 9508-9514 (1989); J. Biol. Chem., 264, 12126-12129 (1989); Hum. Gene Ther., 3, 267-275 (1992); Science, 249, 1285-1288 (1990); Circulation, 83, 2007-2011 (1992). )], Direct DNA uptake or receptor-mediated DNA transfer
- Examples of the substance that inhibits the binding of a ligand to GPR4 include an antibody that recognizes GPR4, a compound that has an antagonistic effect on GPR4, and the like.
- any antibody that recognizes GPR4 can be used, but an antibody that specifically recognizes GPR4 is preferable.
- the antibody may be a polyclonal antibody or a monoclonal antibody. Examples of such an antibody include a neutralizing antibody that recognizes GPR4.
- human chimeric antibodies, humanized antibodies and the like can also be used as the antibodies of the present invention.
- the above antibody can be prepared, for example, according to the following method.
- a polyclonal antibody can be prepared by using a purified preparation of GPR4 or a partial fragment polypeptide thereof, or a peptide having a partial amino acid sequence of GPR4 as an antigen and administering it to an animal.
- Animals to be administered include egrets, goats, rats, mice, hamsters, etc. Can be used.
- the dose of the antigen is preferably 50 to 100 ⁇ g per animal.
- a peptide When a peptide is used, it is desirable to use, as the antigen, a peptide obtained by covalently binding a peptide to a carrier protein such as keyhole helmet haemocyanin or bovine thyroglobulin.
- a peptide serving as an antigen can be synthesized by a peptide synthesizer.
- the administration of the antigen is performed 3 to 10 times every 1 to 2 weeks after the first administration. Blood is collected from the fundus venous plexus 3 to 7 days after each administration, and the reaction of the serum with the antigen used for immunization is determined by enzyme immunoassay [enzyme immunoassay (ELISA): published by Medical Shoin ( 1976), Ant ibodies-A Laboratory Manual, Cold Spring Harbor Laboratory (1988)].
- enzyme immunoassay enzyme immunoassay
- a polyclonal antibody can be obtained by obtaining serum from a non-human mammal whose serum has a sufficient antibody titer against the antigen used for immunization, and separating and purifying the serum.
- Methods for separation and purification include centrifugation, salting out with 40-50% saturated ammonium sulfate, caprinoleic acid precipitation [Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, (1988)], or DEAE Sephapha.
- a rat whose serum shows a sufficient antibody titer is produced. Serve as a source of cells.
- the spleen is removed 3 to 7 days after the last administration of the antigenic substance to the rat showing the antibody titer.
- the spleen is shredded in a MEM medium (manufactured by Nissui Pharmaceutical Co., Ltd.), loosened with forceps, centrifuged at 200 rpm for 5 minutes, and the supernatant is discarded.
- MEM medium manufactured by Nissui Pharmaceutical Co., Ltd.
- the spleen cells of the obtained precipitate fraction are washed with Tris-ammonium chloride buffer (PH 7.65) After removing red blood cells by treating for 1 to 2 minutes, the cells are washed three times with a MEM medium, and the obtained spleen cells are used as antibody-producing cells.
- Tris-ammonium chloride buffer PH 7.65
- myeloma cells use cell lines obtained from mice or rats.
- 8-azaguanine-resistant mouse derived from BALB / c
- myeloma cell line P3-X63Ag8-U1 (hereinafter abbreviated as P3-U1) [Curr. Topics Microbiol. Immunol., 81, 1 (1978), Eur. J Immunol., 6, 511 (1976)], SP2 / 0-Agl4 (SP-2) [Nature, 276, 269 (1978)], P3-X63-Ag8653 (653) [J.
- a purified plate of GPR4 or its partial fragment polypeptide used as an antigen or a peptide having a partial amino acid sequence of GPR4 is coated on an appropriate plate, and the hybridoma culture supernatant or described later Reacting the purified antibody obtained in (d) above as the first antibody, and further as the second antibody, an anti-rat or anti-mouse immunoglobulin antibody labeled with biotin, an enzyme, a chemiluminescent substance or a radioactive compound, etc.
- a reaction according to the labeling substance is carried out, and those which specifically react with the polypeptide used as the antigen are selected as the hybridoma producing the monoclonal antibody used in the present invention.
- hybridoma Using the hybridoma, cloning was repeated twice by the limiting dilution method (first time, using HT medium (medium obtained by removing aminopterin from HAT medium), and second time, using normal medium). Those with a strong antibody titer are selected as the hybridoma strain producing the monoclonal antibody used in the present invention.
- Pristane-treated [0.5 ml of 2,6,10,14-tetramethinolepentadecane (Pri stane) was intraperitoneally administered and bred for 2 weeks]. ).
- the hybridoma cells producing the monoclonal antibody used in the present invention obtained in the above step 5 are injected intraperitoneally with 5 to 20 ⁇ 10 e cells / animal. In 10 to 21 days, Hypridoma develops ascites cancer.
- the ascites is collected from the mouse with ascites tumor and centrifuged at 3,000 rpm for 5 minutes to remove solids.
- a monoclonal antibody can be purified and obtained in the same manner as the method used for the polyclonal antibody.
- the subclass of an antibody is determined using a mouse monoclonal antibody typing kit or a rat monoclonal antibody typing kit.
- Polypeptide amount is calculated from the absorbance of one method or 2 80 nm lorry.
- the above preventive and / or therapeutic agent for asthma containing an antibody recognizing GPR4 can be prepared as follows.
- a medicament containing the antibody as an active ingredient can be administered alone, but usually the active ingredient is one or more pharmacologically acceptable. It is desirable to mix it with the body and provide it as a pharmaceutical preparation manufactured by any of the methods well-known in the art of pharmacy.
- a sterile solution dissolved in water or an aqueous carrier such as an aqueous solution of salt, glycine, glucose, human albumin or the like is used.
- pharmacologically acceptable additives such as buffering agents and tonicity agents to bring the formulation solution closer to physiological conditions, for example, sodium acetate, sodium chloride, sodium lactate, chloride Potassium, sodium tenoate, etc. can also be added. Alternatively, it can be stored after being freeze-dried and dissolved in an appropriate solvent before use.
- Dosage forms include tablets, injections and the like.
- Suitable formulations for oral administration include tablets and the like. Tablets and the like are made up of excipients such as lactose and mannitol, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, surfactants such as fatty acid esters, glycerin, etc. It can be manufactured by using a plasticizer or the like as an additive.
- Formulations suitable for parenteral administration include injections and the like. For example, an injection is prepared using a carrier or the like comprising a salt solution, a pudose solution or a mixture of both.
- the components exemplified as additives in oral preparations can be added.
- the dose or frequency of administration varies depending on the desired therapeutic effect, administration method, treatment period, age, body weight, etc., but is usually 10 / g / kg to 8 mg / kg per day for an adult.
- a substance that suppresses the function related to signal transduction caused by the constitutive activity of GPR4 The quality can also be obtained by searching for a substance that can suppress signal transduction caused by the constitutive activity.
- Examples of the compound having an antagonistic action on GPR4 include a compound represented by the formula (I).
- the compound represented by the formula (I) is referred to as compound (I). The same applies to compounds of other formula numbers.
- the lower alkyl moiety of the lower alkyl and the lower alkanol includes, for example, a linear or branched alkyl having 1 to 10 carbon atoms.
- a linear or branched alkyl having 1 to 10 carbon atoms specifically, methyl, ethinole, propynole, isopropynole, petitnole, Isobutyl, sec-butyltinole, tert-butylinole, pentinole, isopentinole, neopentinole, hexinole, heptyl, octyl, isooctyl, noel, desinole, and the like.
- cycloalkyl examples include cycloalkyl having 3 to 8 carbon atoms.Specifically, cyclopropyl, cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctynole, etc. Is mentioned.
- Examples of the lower alkenyl include straight-chain, branched or cyclic alkenyl having 2 to 8 carbon atoms, and specific examples thereof include vinyl, aryl, 1-propenyl, butenol, and pentenyl. Hexeninole, hepteninole, octeninole, cyclohexenyl, 2,6-octactenyl, and the like.
- Examples of the lower alkynyl include straight-chain or branched alkynyl having 2 to 8 carbon atoms, and specific examples thereof include ethynyl, propininole, butyr, pentynyl, hexynyl, heptynyl, octynyl and the like. Is mentioned.
- Halogen represents fluorine, chlorine, bromine and iodine atoms.
- Examples of the aryl and the aromatic ring formed by joining together two adjacent carbon atoms and removing one hydrogen atom include monocyclic groups having 6 to 14 carbon atoms, Examples include bicyclic or tricyclic aryls, and specific examples include phenyl, naphthyl, indenyl, and anthranyl.
- alkylene portion of aralkyl and heterocyclic alkyl has the same meaning as the above-mentioned definition of lower alkyl (i) except that one hydrogen atom is removed.
- the aryl moiety of the aralkyl includes, in addition to the groups mentioned in the definition of the aryl (vi), for example, a bicyclic fused ring in which the aryl is fused with a cycloalkyl. Specific examples thereof include indanyl, 1,2,3,4-tetrahydrodronaphthyl, 6,7'8,9-tetrahydro-5-I-I-benzocycline, and the like. Can be
- heterocyclic group and the heterocyclic group portion of the heterocyclic alkyl and the group obtained by removing one hydrogen atom from a heterocyclic ring formed by joining together two adjacent carbon atoms include, for example, a nitrogen atom A 5- or 6-membered monocyclic heterocyclic group containing at least one atom selected from an oxygen atom and a sulfur atom, a bicyclic or tricyclic fused 3- to 8-membered ring and nitrogen And a condensed heterocyclic group containing at least one atom selected from an atom, an oxygen atom and a sulfur atom.
- pyridyl pyrazinyl, pyrimidinyl, pyridazinyl, benzodimidazolyl, and 2- Oxobenzimidazolyl, benzotriazolyl, benzofuryl, benzocenyl, prenyl, benzoxazolyl, benzothiazolyl, benzodioxolyl, indazolyl, inn Ril, isoindolyl, quinolinole, isoquinolyl, phthalazinyl, naphthyl ridinyl, quinoxalinyl, pyrrolyl, pyrazolyl, quinazolinyl, cinnolinyl, triazolyl, tetrazolyl, imidazolyl, oxazolyl, thiazolyl, thiazolyl, thiazolyl Chenyl, furyl, pyrrolidinyl, 2,5-dioxopyrroli
- heterocyclic group formed together with the adjacent nitrogen atom for example, a 5- or 6-membered monocyclic heterocyclic group containing at least one nitrogen atom (the monocyclic heterocyclic group) Heterocyclic groups may contain other nitrogen, oxygen or sulfur atoms), bicyclic or tricyclic condensed 3- to 8-membered ring containing at least one nitrogen atom Heterocyclic group (the condensed heterocyclic group may contain another nitrogen atom, oxygen atom or sulfur atom) and the like, and specifically, pyridyl, tetrahydropyridyl, indolinyl and the like.
- Substituents in the substituted lower alkyl and the substituted lower alkyl are the same or different and include, for example, cycloalkyl, lower alkanoyl, lower alkoxy, aryloxy, substituted aryloxy having 1 to 3 substituents [the substituted aryloxy] And the same or different, for example, lower alkyl, lower alkoxy, lower alkoxycarbonyl, halogen, cyano, nitro, hydroxy, carboxy, amino and the like having 1 to 3 substituents. No.
- the lower alkyl has the same meaning as the lower alkyl (i)
- the halogen has the same meaning as the halogen (V)
- the lower alkyl part of the lower alkoxy and the lower alkoxycarbonyl has the same meaning as the lower alkyl (i).
- Aralkyloxy, substituted aralkyloxy [The substituents in the substituted aralkyloxy may be the same or different and include, for example, lower alkyl, lower alkoxy, lower alkoxycarbonyl, lower alkoxycarbonyl, halogen, cyano, nitro having 1 to 3 substituents. B, hydroxy, carboxy, amino and the like.
- lower alkyl has the same meaning as the above lower alkyl (i), and phenyl and benzene have the same meanings as the above-mentioned hachigen (V).
- the lower alkyl part of the lower alkoxy and the lower alkoxy carbonyl is the above lower alkyl (i).
- the groups may be the same or different and include, for example, hydroxy having 1 to 3 substituents, halogen, etc.], substituted lower alkanols [the substituents in the substituted lower alkanols may be the same or different, Examples thereof include halogens having 1 to 3 substituents], mono- or di-lower alkylamino, lower alkynole Norehoniru, lower ⁇ Roh gravel Rusuru alkylsulfonyl, lower alkoxycarbonyl amino And mono- or di-lower alkylaminocarbonyl, mono- or di-lower alkylaminocarbonyloxy, heterocyclic group and the like.
- the lower alkyl moiety of the lower alkylsulfininole, lower anoroxycarbonylamino and lower alkylamino is the above aryl (vi), cycloalkyl (ii), halogen (v), heterocyclic group (ix), And lower alkyl (i), and the alkylene portion of aralkyloxy has the same meaning as the lower alkyl (i) except for one hydrogen atom.
- the lower alkyl portion of the mono- or di-lower alkylamino, mono- or di-lower alkylaminocarbonyl and mono- or di-lower alkylaminocarbonyloxy is the same as the lower alkyl (i), respectively.
- the two lower alkyl moieties of di-lower alkylaminocarbonyl and di-lower alkylamino power may be the same or different.
- the substituents in a ring group, a substituted aromatic ring each formed with two adjacent carbon atoms, and a substituted heterocyclic ring each formed with two adjacent carbon atoms are: In addition to the groups mentioned in the definition of the substituent (xi) in the substituted lower alkyl, lower alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic group, substituted heterocyclic group, heterocyclic alkyl, substituted heterocyclic alkyl And so on.
- the substituent in the substituted aryl and the substituted heterocyclic group formed together with the adjacent nitrogen atom is a lower alkyl [the lower alkyl has the same meaning as the above lower alkyl (i).
- substituted lower alkyl wherein the lower alkyl is as defined above for the lower alkyl (i)
- the groups are the same or different, and include, for example, halogens, hydroxy, carboxy, lower alkoxycarbonyl and the like having 1 to 3 substituents.
- halogen has the same meaning as the above-mentioned halogen (V)
- the lower alkyl part of the lower alkoxycarbon has the same meaning as the above-mentioned lower alkyl (i).
- the lower alkyl, aryl, heterocyclic group and the heterocyclic group portion of the heterocyclic alkyl, the aralkyl and the alkylene portion of the heterocyclic alkyl, and the aralkyl portion of the aralkyl shown above are the lower alkyl (i) and the aryl, respectively.
- the substituent in the substituted aryl, the substituted aralkyl, the substituted heterocyclic group, and the substituted heterocyclic alkyl may be the same or different, for example, lower alkyl having 1 to 3 substituents [the lower alkyl is the lower alkyl. (The lower alkyl portion of the lower alkoxy is the same as the lower alkyl (i)), halogen, and the like (the halogen is the same as the halogen (V)). No.
- Examples of the quaternary ammonium salt of compound (I) include a lower alkyl halide (the lower alkyl and the halogen are the same as defined above), a halogenated aralkyl, and the like at the basic site of compound (I). (The halogen and the aralkyl are the same as defined above), and quaternary ammonium salts to which hydroxy lower alkyl (the lower alkyl is the same as defined above) and the like are not particularly limited.
- the quaternary ammonium salt obtained by reacting the quaternary ammonium salt obtained by reacting the compound (I) with a pyrrolidino group with the compound (I) with iodide thiol iodide ions and hydroxide ions are exchanged. And the like.
- a non-toxic, water-soluble salt is preferable.
- Alkaline earth metal salts such as metal salts, magnesium salts and calcium salts, metal salts such as aluminum salts and zinc salts, organic amines such as ammonium salts such as ammonium and tetramethylammonium, morpholine addition salts and piperidine addition salts
- Addition salts or amino acid addition salts such as glycine addition salts, phenylalanine addition salts, lysine addition salts
- R 9 represents lower alkyl, aryl or benzyl
- R 1 () and R 11 The same or different, lower alkyl or cycloalkyl, or R 1Q and R 11 taken together with the adjacent nitrogen atom to form a heterocyclic group, and U is halogen, alkoxysulfonyloxy, aryloxy Represents sulfoninoleoxy, anolequinolesulfoninoleoxy or arylsulfonyloxy
- lower alkyl, cycloalkyl and halogen are as defined above, respectively.
- the alkyl part of the alkoxysulfonyloxy and alkylsulfonyloxy, and the aryl part of the aryloxysulfonyloxy and arylsulfonyloxy have the same meanings as the lower alkyl and aryl, respectively. It is.
- the heterocyclic group formed together with the adjacent nitrogen atom has the same meaning as described above.
- compound (Ilia) as a raw material and reacting it with 1 equivalent to a large excess of YH (where Y is as defined above) according to the method disclosed in JP-A-7-ei983. As a result, compound (IV) can be obtained.
- the compound (Ilia) can be synthesized by the method disclosed in JP-A-7-61983 or a method analogous thereto.
- reaction usually proceeds well under acidic conditions, it is preferable to add an acid such as hydrochloric acid, acetic acid, or trifluoroacetic acid into the reaction system as needed.
- the reaction is usually performed at a temperature between 0 ° C and the boiling point of the solvent used in the reaction, preferably at a temperature between room temperature and 80 ° C, and is completed in 5 minutes to 100 hours.
- Inert solvents include, for example, water, methanol, ethanol, acetic acid, trifluoroacetic acid, dichloroethane, Cross-linked form, tetrahydrofuran, dimethinoreacetamide, dimethylformamide, acetone, and the like can be used alone or as a mixture, and a mixed solvent of black-formed form and acetic acid is preferably used.
- Compound (g) can be produced from compound (Ib) by the method shown below.
- Compound (Ib) is dissolved in an inert solvent in an amount of 1 equivalent to a large excess of R 8 U (wherein R 8 and U have the same meanings as described above), and usually the boiling point of the solvent used in the reaction from 110 ° C.
- the compound (Ic) can be obtained by reacting at a temperature between the above, preferably at room temperature, for 1 to 48 hours.
- inert solvent examples include water, methanol, ethanol, benzene, tonolen, xylene, ethynole acetate, hexane, acetonitrile, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, and 1,4.
- Monodioxane, tetrahydrofuran, dimethylacetamide, dimethylformamide, acetone, and the like can be used alone or in combination.
- ethyl acetate, dichloromethane, chloroform, and the like are used.
- Compound (Ib) can be produced from compound (Ic) by the method shown below. Manufacturing method 3
- Compound (I-c) is reacted with 1 equivalent to a large excess of R 5 RH (in the formula, and R 6 are each as defined above) in an inert solvent, and the solvent used for the reaction is usually used at a temperature of 1-10 ° C.
- the compound (ib) can be obtained by reacting at a temperature between the boiling points, preferably between 20: and 100 ° C, for 1 to 100 hours.
- inert solvent examples include water, methanol, ethanol, benzene, tonolene, xylene, ethynole acetate, hexane, acetonitrile, dichloromethane, dichloroethane, black form, carbon tetrachloride, 1 , 4-dioxane, tetrahydrofuran, dimethylacetamide, dimethinoleformamide, acetone and the like are used alone or as a mixture, and preferably, chloroform and dimethylformamide are used. Since the reaction usually proceeds well under basic conditions, it is desirable to add an appropriate base into the reaction system as needed.
- Bases include, for example, triethylamine, disopropylethylamine, pyridine, N-methylmorpholine, potassium carbonate, sodium hydride, lithium hydride, calcium hydride, diisopropylethylamine. , 1,8-diazabicyclo [5.4.0] indene 7-ene and the like can be used, and among them, triethylamine is preferable.
- Compound (I-e) can be produced from compound (I-b) using compound (I-d) by the method shown below.
- R 14 and R 15 are the same or different and are hydrogen, substituted or unsubstituted lower alkyl, substituted Or unsubstituted cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic alkyl, or R 14 and R 15 may form a substituted or unsubstituted heterocyclic ring with the adjacent CH (CH 2 ) m N.
- R 16 may be hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted Represents cycloalkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aryl, m is 0 to 3 Represents an integer)
- Lower alkyl, cycloalkyl, lower alkenyl, lower alkynyl, aralkyl, heterocyclic alkyl, and aryl are the same as defined above, and their substituents are also defined as above.
- Examples of the substituted or unsubstituted heterocyclic ring formed by R 14 and R 15 together with adjacent CH (CH 2 ) n N include tetrahydropyridine, pyrrolidine, piperidin, and homopiperidine. , Piperazine, homopiperazine, monorephorin, thiomonoreolin, perhydroazepine, penolehydroazozin, tetrahydroquinoline, tetrahydroisoquinoline, etc. It has the same meaning as the substituent of the heterocyclic group formed together with the atom.
- Compound (Id) is placed in an inert solvent, usually at a temperature between 78 ° C and 40 ° C, at 2 to 4 equivalents of lithium aluminum hydride, aluminum dilithium aluminum hydride, preferably aluminum diisopropyl hydride. Treatment in the presence of reducing agent such as dimethyllithium for 10 minutes to 24 hours, preferably 1 to 3 hours. Compound (Ie) can be obtained.
- inert solvent for example, dichloromethane, chloroform-form, carbon tetrachloride, dichloroethane, benzene, tonolene, xylene, tetrahydrofuran, getyl ether, etc. can be used alone or in combination.
- dichloromethane or toluene is used.
- Compound (If) can be produced from compound (Id) by the following method.
- Compound (Id) in an inert solvent usually at a temperature between 0 ° C and the boiling point of the solvent used in the reaction, preferably at a temperature between room temperature and 100 ° C, from 1 equivalent to a large excess of the appropriate salt Compound (If) can be obtained by treating for 1 to 48 hours, preferably for 1 to 3 hours in the presence of a group.
- Suitable bases include, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide, potassium carbonate, cesium carbonate, sodium methoxide, and the like.
- Examples include sodium hydroxide.
- the inert solvent for example, water, tetrahydrofuran, dimethyl ether, methanol, ethanol, ethanol, dichloromethane, dichloroethane, benzene, tonylene, xylene, etc. are used alone. Or tetrahydrofuran or methanol, or a mixed solvent thereof with water. From the compound (ic), the compound (i-h) can be produced from the compound (i-g) by the following method.
- alkyl in trialkylsilyl and trialkyltin has the same meaning as the lower alkyl.
- Examples of aluminum metal include sodium and steel.
- the compound (Ih) can be obtained by reacting in the presence for 1 to 200 hours, preferably for 3 to 48 hours.
- Suitable additives include, for example, silicon tetrachloride, lithium chloride, aluminum chloride, ammonium chloride, trialkyltin chloride, dialkyltin oxide, trialkylaluminum, triethylamine hydrochloride, Lietilamine 'hydrobromide, sodium hydride, potassium tert-butoxide, sodium hydroxide, zinc bromide, etc., preferably, ammonium chloride, dialkyltin oxide, etc. Is mentioned.
- inert solvent examples include water, acetonitril, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, Dimethyl snorreoxide, acetic acid, glacial acetic acid, tetrahydrofuran, benzene, toluene, xylene and the like can be used alone or as a mixture, and dimethylformamide or toluene is preferably used.
- Compound (ii) can be produced from compound (ic) by the following method.
- R 18 is a substituted or unsubstituted lower alkyl.
- Q is an alkali metal or an alkaline earth metal
- p is 1 if Q is an alkali metal
- p is 2 if Q is an alkaline earth metal.
- alkali metal is synonymous with the above-mentioned alkali metal, and examples of the alkaline earth metal include magnesium and calcium.
- inert solvent for example, dimethylacetamide, N-methyl-2-pyrrolidone, dimethylsulfoxide and the like can be used alone or in combination, and dimethylsulfoxide is preferably used.
- Production of compound (ij) from compound (Ic) by the following method Can be.
- Compound (Ic) in an inert solvent at a temperature between 0 ° C and the boiling point of the solvent used in the reaction Preferably at a temperature between 30 ° C and 80 ° C, 1 equivalent to a large excess, preferably 1 to 100 hours, preferably in the presence of 2 to 8 equivalents of R 7a SH (wherein R 7a has the same meaning as described above) and 1 to large excess, preferably 1 to 3 equivalents of a suitable base.
- the compound (Ij) can be obtained by reacting for 3 to 72 hours.
- Suitable bases include, for example, triethylamine, diisopropylethylamine, pyridine, N-methylmorpholine, potassium carbonate, sodium hydride, potassium hydride, hydrogenation calcium, Jie Sopuro Piruechiruami emissions, 1, 8 - Jiazabishiku b [5-4.0] Undekku one 7-E down or the like can be used, among others 1, 8-Jiazabishiku port [5. 4.0] Undekku one 7 __En is preferred.
- inert solvent for example, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, benzene, toluene, xylene, ethyl ethyl sulphate, dimethylinolacetamide, ⁇ -methyl-2-pyrrolidone, dimethyl sulfoxide, etc.
- inert solvent for example, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, benzene, toluene, xylene, ethyl ethyl sulphate, dimethylinolacetamide, ⁇ -methyl-2-pyrrolidone, dimethyl sulfoxide, etc.
- black form is used.
- compound (1-1;) can be produced from compound (Ik) by the following method.
- Compound (I-1) can be produced by performing the same reaction as in Step 6 of Production Method 5 using compound (I-k).
- Compound (i-m) can be produced from compound (i-i) by the following method.
- Compound (I-m) can be produced by performing the same reaction as in Step 6 of Production Method 5 using compound (I-i).
- Compound (i-n) can be produced from compound (I-m) by the following method. '
- R 7c represents a group obtained by removing hydrogen from the definition of R 7
- Compound (Im) is prepared in an inert solvent at a temperature between 0 ° C and the boiling point of the solvent used in the reaction, preferably at a temperature between room temperature and 80 ° C, from 1 equivalent to a large excess, preferably from 1 to In the presence of 3 equivalents of a suitable base, 1 equivalent to a large excess, preferably 1 to 3 equivalents of R 7 ⁇ ; U (wherein R 7 and U are as defined above), and 1 to 48 hours The reaction is preferably performed for 3 to 24 hours to obtain the compound (In).
- Suitable bases include, for example, potassium carbonate, sodium hydride, lithium hydride, calcium hydride, lower alkyl lithium, and the like.
- the inert solvent include dichloromethane, chloroform, carbon tetrachloride, dichloroethane, benzene, toluene, xylene, ethyl acetate, dimethylinolenolemamide, dimethylacetamide, and N-methylol-2-amide.
- Pyrrolidone, tetrahydrofuran, getyl ether and the like can be used alone or as a mixture, and chloroform is preferably used.
- R 2 , RR 4 , X and Y are each as defined above).
- Compound (I-ma) is prepared in an inert solvent at a temperature between 0 ° C and the boiling point of the solvent used in the reaction, preferably at a temperature between room temperature and 60 ° C, from 1 equivalent to a large excess, preferably Compound (Io) can be obtained by treating in the presence of 3 to 6 equivalents of an appropriate oxidizing agent for 1 to 48 hours, preferably for 3 to 24 hours.
- Suitable oxidizing agents include, for example, manganese dioxide, chromic acid, pyridinium chromate, pyridinium chromate, potassium permanganate, sulfur trioxide-pyridin, and oxone. Is manganese dioxide.
- inert solvent examples include dichloromethane, black form, carbon tetrachloride, dichloroethane, benzene, toluene, xylene, ethyl acetate, acetic acid, propionic acid, butyric acid, trifluoroacetic acid, water, Pyridine, dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, getyl ether, etc. can be used alone or in combination. Preferably, dimethylformamide, tetrahydrofuran and the like are used.
- Compound (Ip) can be produced from compound (1-0) by the method shown below.
- Suitable dehydrating agents include, for example, acetic anhydride, phthalic anhydride, sodium hydrogen sulfate, oxone, sodium formate, dialkyltin oxide, alumina, silica gel, sodium acetate, formamide, pentaamide
- Illustrative are phosphorus oxide, iron (111) chloride, formic acid, acetic acid, propionic acid, oxychlorinated phosphorus, paratoluenesulfonic acid and the like, preferably acetic anhydride, phthalic anhydride and the like.
- Suitable bases include, for example, triethylamine, pyridine, sodium hydride, hydride and the like, and preferably triethylamine or pyridine.
- Inert solvents include, for example, dichloromethane, chloroform, carbon tetrachloride, dichloromethane, benzene, toluene / leene, xylene, nitrobenzene, acetonitril, ethyl acetate, acetic acid, propionic acid, Butyric acid, trifluoroacetic acid, pyridin, dimethylformamide, dimethylacetamide, N-methinole-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, gethyle tenorene, methanolol, ethanol, propanol And the like can be used alone or in combination.
- acetonitrile, dimethylformamide and the like are used.
- Compound (I-q) can be produced from compound (I-p) by the following method.
- Compound (I_q) can be produced by performing the same reaction as in Step 7 of Production Method 6 using compound (I-P).
- Compound (i-r) can be produced from compound (I-c) by the method shown below.
- R 2 , R 3 , R 4 , R 5b , R 6b , R 8 , U, n, X and Y are as defined above, and Q a is an alkali metal as defined above
- Inert solvents include, for example, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, benzene, tonolen, xylene, dimethinolehonolemamide, dimethylacetamide, N-methyl-2-pyrrolidone, 1 , 4-Dioxane, Te Trahi Drofuran or the like can be used alone or as a mixture, and dimethylformamide or the like is preferably used.
- Compound (is) can be produced from compound (ir) by the following method.
- R 2 , R 3 , R 4 , T, n, X and Y are each as defined above).
- Compound (I-s) can be produced by performing the same reaction as in Step 7 of Production Method 6 using compound (I-r).
- Compound (I-1) can be produced from compound (Ir) by the following method.
- Compound (I-1) can be produced by performing the same reaction as in Step 6 of Production Method 5 using compound (I-r).
- Compound (Iu) can be produced from compound (nib) by the following method.
- R 2 R 3, R 4, R 5, R 6, R 5b, R 6b, R 7c, R 8, R 9, R 10 R u, R 18, Q, p, U, X and Y is as defined above.
- Compound (V) can be produced by performing the same reaction as in step 8 of production method 7 using compound (Illb).
- Compound (VI) can be produced by performing the same reaction as in Step 6 of Production Method 5 using Compound (V).
- Compound (VII) can be produced by performing the same reaction as in step 13 of production method 12 using compound (VI). Process 2 2 ⁇
- Compound (VII) in an inert solvent usually at a temperature between 0 ° C and 80 ° C, with 2-4 equivalents of silver nitrate, silver oxide (1), silver oxide ( ⁇ ), chromic acid, and chromium chromium Pyridinium acid, pyridinium dichromate, potassium permanganate, sodium periodate, sodium perchlorate, hydrogen peroxide, sodium chlorite
- Compound (VI II) can be obtained by treating for 10 minutes to 24 hours, preferably 1 to 4 hours in the presence of an oxidizing agent such as stream, preferably silver nitrate or sodium perchlorate. Can be manufactured. If necessary, add 0.1 to 4 equivalents of organic substances such as acetic acid or inorganic substances such as sulfuric acid, sodium dihydrogen phosphate, sulfamic acid, and lutemium oxide as additives. Is also good. .
- inert solvent examples include getyl ether, tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, dimethylsulfoxide, benzene, tonolenene, xylene, dichloromethane, chlorofozolem, 1,2-dichloroethane, acetonitrile, ethyl acetate, methyl acetate, methylethyl ketone, hydrochloric acid, acetic acid, acetic anhydride, sulfuric acid, water, etc., preferably, acetonitrile, water, etc. These can be used alone or as a mixture. ⁇ Step 2 3>
- the compound (VIII) is reacted with 1 to 20 equivalents of a halogenating agent for 10 minutes to 24 hours in an inert solvent, usually at a temperature between 0 ° C and 80 ° C, preferably at room temperature, and then 1 equivalent Compound (IX) can be produced by reacting with a large excess of R 7c; 0H (wherein is as defined above).
- halogenating agent examples include thiol chloride, oxalyl chloride, oxylin chloride and the like, and preferably thiolonyl chloride.
- inert solvent examples include dichloromethane, chlorophonolem, tetrahydrofuran, dimethylformamide, dimethylacetamide, 1,4-dioxane, acetonitrile, benzene, toluene, xylene, etc. These can be used alone or as a mixture.
- Preferred examples of the inert solvent include dichloromethane.
- Compound (IX) is used to perform the same reaction as in Step 2 of Production Method 1. Compound (X) can be produced.
- Compound (XI) can be produced by performing the same reaction as in step 3 of production method 2 using compound (X).
- Compound (I-u) can be produced by performing the same reaction as in step 1 of production method 1 using compound (XI).
- Compound (i-v) can be produced from compound (I-u) by the following method.
- Compound (I-v) can be produced by performing the same reaction as in Step 6 of Production Method 5 using compound (I-u).
- Compound (i-w) can be produced from compound (I-v) by the following method.
- the compound (I-V) is reacted with 1 to 20 equivalents of a halogenating agent for 10 minutes to 24 hours in an inert solvent, usually at a temperature between 0 ° C and 80 ° C, preferably at room temperature.
- the compound (Iw) can be produced by reacting with 1 equivalent to a large excess of R 5a R 6a NH (wherein R 5a and R 6a have the same meanings as described above). If necessary, one equivalent to a large excess of a suitable base may be added.
- Examples of the nodulating agent include thionyl chloride, oxalyl chloride, and oxylin chloride, and preferably thionyl chloride.
- Suitable bases include, for example, pyridine, triethylamine, diisopropylethylamine, N-methylmorpholine and the like, preferably triethylamine.
- Examples of the inert solvent include dichloromethane, chloroform, tetrahydrofuran, dimethylformamide, dimethylacetamide, 1,4-dioxane, acetonitrile, benzene, toluene, and xylene. These can be used alone or in combination. Preferred examples of the inert solvent include dichloromethane.
- compound (Iw) In the production of compound (Iw), a method commonly used in peptide chemistry can also be used. That is, in an inert solvent for compound (IV), 1 to 10 equivalents of R 5a R 6a NH (in the formula, R 5a and R 6a are each as defined above) together with 0.5 to 10 equivalents of an appropriate condensing agent.
- the compound (IW) can be obtained usually by reacting at a temperature between 0 ° C and 50 ° C for 10 minutes to 70 hours.
- inert solvent examples include getyl ether, tetrahydrofuran, 1,4-dioxane, dimethylformamide, dimethylacetamide, dimethylsnorefoxide, benzene, tonolene, xylene, acetonitrinolole, and ethyl acetate. And tetrachlorofuran, dimethylformamide, and the like. Preferred are tetrahydrofuran, dimethylformamide and the like.
- Suitable condensing agents include, for example, 1,3-dicyclohexyl carbodiimide, 1-ethyl-3_ (3-dimethylaminopropyl) carbodiimide hydrochloride, 1-ethyl-3- (3-dimethylaminopropyl Pill) force-bonded polystyrene resin (EDC resin) and the like.
- EDC resin force-bonded polystyrene resin
- EDC resin can be produced by the method described in Tetrahedron Letters, Vol. 34, No. 48, p. 7685 (1993).
- Compound (I-y) can be produced from compound (I-X) in compound (I) by the following method.
- R 3 , R ⁇ n, X and Y are as defined above, and R 22 and R 23 are the same or different and are hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted Represents a substituted cycloalkyl, a substituted or unsubstituted lower alkenyl, a substituted or unsubstituted lower alkynyl, a substituted or unsubstituted aralkyl, or a substituted or unsubstituted heterocyclic alkyl)
- lower alkyl, cycloalkyl, lower alkenyl, lower alkyl, aralkyl, and heterocyclic alkyl have the same meanings as described above, and their substituents have the same meanings as described above.
- Step 2 9 Compound (I- x) in an inert solvent, one equivalent to a large excess, preferably (wherein, R 22 and R 23 each have the same meanings as defined above) 1 to 10 equivalents of R 22 R 23 C0 and , 1 equiv to large excess, preferably in the presence of 1-3 equivalents of a suitable reducing agent, usually - 7 8 temperature between ° Celsius to 100 ° C, a temperature of preferably between at 0 ° Celsius to 50
- the compound ( ⁇ -y) can be obtained by reacting for 10 minutes to 48 hours.
- Suitable reducing agents include, for example, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride, and preferably sodium borohydride.
- a catalyst amount to a solvent amount preferably 0.5 equivalent to a solvent amount, may be added to a suitable acid.
- suitable acids include, for example, formic acid, acetic acid, trifluoroacetic acid, propionic acid, hydrochloric acid and the like, and preferably acetic acid.
- Inert solvents include, for example, dichloromethane, chloroform, carbon tetrachloride, dichloroethane, benzene, tonolene, xylene, etinoleethenol, 1,4-dioxane, dimethylformamide, dimethylacetamide , Acetonitrile, hexane, formic acid, acetic acid, trifluoroacetic acid, propionic acid, hydrochloric acid and the like are exemplified, and these can be used alone or in combination.
- tetrahydrofuran, acetic acid and the like are mentioned.
- each functional group in the compound (I) and the starting compound and the conversion of the functional group contained in the substituent may be carried out by a known method [for example, "Compliance” Organic Transformation. Second Edition (Comprehens ive Organization Transformation ons, the second edition), by RC Larock, Shonn Wiley and Sands Incorporated (John) Wiley & Sons Inc.) (1999)].
- the compound (I) having a desired functional group at a desired position can be obtained by appropriately combining the above methods and the like.
- Isolation and purification of intermediates and products in the above production method are performed by appropriately combining methods used in ordinary organic synthesis, for example, filtration, extraction, washing, drying, concentration, crystallization, various types of mouth chromatography, etc. be able to. Purification methods commonly used in general parallel synthesis methods such as scavenger resin and ion exchange It can also be performed by a purification method using a replacement resin. In addition, the intermediate can be subjected to the next reaction without purification.
- Some of the compounds (I) may exist as isomers such as positional isomers, geometric isomers, optical isomers or tautomers, but all possible isomers including these, and the isomers Mixtures in any ratio of can be used in the prophylactic and Z or therapeutic agents for asthma of the present invention.
- salt of compound (I) When it is desired to obtain a salt of compound (I), if the salt of compound (I) is obtained, it may be purified as it is, and if compound (I) is obtained in a free form, the compound may be purified.
- (I) may be dissolved or suspended in a suitable solvent, and then isolated and purified by adding an acid or a base.
- Compound (I) or a pharmacologically acceptable salt thereof may be present in the form of an adduct with water or various solvents, and these adducts are also used in the prevention and / or prevention of asthma of the present invention. Or it can be used as a therapeutic agent.
- Tables 1 to 13 show specific examples of the compound (I) used as a prophylactic and / or therapeutic agent for asthma of the present invention.
- the range of compounds used is not limited to these compounds.
- FIG. 1 shows the inhibitory effect of Compound 1 (intraperitoneal administration) on antigen-induced airway constriction.
- the symbols (#, **) represent the following meanings, respectively.
- FIG. 2 shows the inhibitory effect of compound 1 (oral administration) on antigen-induced airway constriction.
- the symbols (#, #, *) mean the following, respectively.
- FIG. 3 shows the inhibitory effect of compound 1 on antigen-induced airway hyperresponsiveness.
- the sign (#) has the following meaning.
- FIG. 4 shows the inhibitory effect of compound 1 on antigen-induced airway eosinophil infiltration ⁇
- the symbols (# # #, * * *) mean the following, respectively.
- Test example 1 GPR4 antagonism
- the activity (antagonism) of the test compound was represented by an inhibition rate calculated based on the count (seconds) with and without the addition of 17-estradiol as shown in the following formula. IC 5.
- the value was calculated from the inhibition rate by the linear approximation analysis of the Logit-Log conversion method.
- A, B, and C represent the following meanings, respectively.
- mice BALB / c male mice (7 weeks old) were mixed with 50 g ovalbumin and 1 mg aluminum hydroxide in a physiological saline solution (Otsuka Ishoku Injection, Otsuka Pharmaceutical Co., Ltd.). The mice were sensitized by intraperitoneal administration twice, and the last sensitization was carried out for 14 minutes. After 13 days, 18 days and 22 days later, 1% ovalbumin saline solution or saline solution (negative control group) was inhaled for 30 minutes each for antigen-antibody reaction. Evoked.
- a physiological saline solution Otsuka Ishoku Injection, Otsuka Pharmaceutical Co., Ltd.
- Each dose was orally administered once per kg (as a solution suspended in 0.5% aqueous methylcellulose solution).
- a vehicle was administered to the positive control group instead of the test compound suspension.
- oral administration was performed once one hour before antigen inhalation 14 days after the last sensitization, and intraperitoneal administration was performed once a final sensitization.
- Vehicle was administered once 30 minutes before inhalation of antigen 14 days after immunization When airway hyperresponsiveness and eosinophil infiltration in the airway were measured, 14 days, 18 days, and 22 days after the last sensitization The vehicle was administered 1 hour before and 6 hours after each antigen inhalation).
- the airway contraction reaction was measured for 30 minutes by measuring the airway resistance (penh) using a mouse respiratory function analyzer (BioSystem XA; Buxco Electronics, Inc., Sharon, CT, USA) for 30 minutes immediately after inhalation of the antigen 14 days after the last sensitization.
- the area under the curve (AUC._ 3. nin) was evaluated by calculating the.
- airway hyperresponsiveness and eosinophil infiltration in bronchoalveolar lavage fluid were evaluated 24 hours after the last antigen inhalation.
- the airway hypersensitivity test was performed using a mouse respiratory function analyzer (BioSystem XA; Buxco Electronics, Inc.) to measure the airway response after inhalation of 1.5-25 mg / mL methacolin for 3 minutes (inhalation 24 hours after the last sensitization 22 days). , Sharon, CT, USA) and evaluated by calculating the area under the curve (AUC) from the mesacollin dose-airway response curve.
- AUC area under the curve
- eosinophil infiltration the total number of cells in the collected alveolar lavage fluid was measured using an automatic blood cell counter (Celltac ⁇ -6158; Nihon Kohden, Tokyo), and the smear was then transferred to Cytospin3 (Shandon, Inc., Pittsburgh). , PA, USA) and morphologically classified and evaluated under a microscope. Eosinophil count was calculated by multiplying the total cell count by the percentage of eosinophil cells. The test was performed with 10 animals per group.
- FIG. 1 The results for airway constriction are shown in Fig. 1 (intraperitoneal administration) and Fig. 2 (oral administration), the results for airway hyperreactivity are shown in Fig. 3, and the results for airway eosinophil infiltration are shown in Fig. 4.
- nin (19.61 ⁇ 0.75, mean soil standard error) is the AUC of the negative control group. _ 3 .
- the AUC of airway hyperresponsiveness in the positive control group (335.13 ⁇ 52.6, mean soil standard error) was significantly increased compared to the AUC of the negative control group (184.7 ⁇ 27.5).
- AUC of the 1 administration group was 243.23 ⁇ 48.7 And reduced airway hyperreactivity by 60% compared to the positive control group.
- the AUC of the prednisodin-administered group was 269.12 ⁇ 46.7, which suppressed airway hyperreactivity by 43% compared to the positive control group.
- Compound 1 administration group and Puredonizo port number of eosinophils in the emissions treatment group 10 5 each per individual 0.92 Sat 0. 26 X, 0. 76 was ⁇ 0. 25 x 10 5.
- the medicament according to the present invention comprises a nitrogen-containing tricyclic compound represented by the formula (I) or a quaternary ammonium salt or a pharmaceutically acceptable salt thereof, and a hydrate or a hydrate thereof. And a substance selected from the group consisting of solvates as an active ingredient.
- the above-mentioned substance which is an active ingredient may be administered as it is, but generally, the above-mentioned substance which is an active ingredient and one or more additives for pharmaceutical preparations are used. It is desirable to administer it in the form of a pharmaceutical composition containing the same.
- Such a pharmaceutical composition can be manufactured according to a method well known or commonly used in the field of pharmaceuticals.
- the medicament according to the present invention in the form of a pharmaceutical composition may contain one or more active ingredients of another medicament.
- the medicament of the present invention is applicable to mammals including human.
- the administration route of the medicament of the present invention is not particularly limited, and the most effective administration route for treatment and / or prevention can be appropriately selected from either oral administration or parenteral administration such as intravenous administration.
- preparations suitable for oral administration include, for example, tablets and the like, and examples of preparations suitable for parenteral administration include, for example, injections.
- excipients such as lactose and mannite
- disintegrants such as starch
- lubricants such as magnesium stearate
- binders such as hydroxypropyl cellulose; And the like
- a surfactant such as glycerin; and the like.
- preparations suitable for parenteral administration can be prepared preferably using an aqueous medium isotonic with human blood.
- an injection is prepared as a solution, suspension or dispersion using an aqueous medium selected from a salt solution, a pudose solution, a mixture of salt water and a pudose solution together with appropriate auxiliaries according to a conventional method.
- parenteral preparations for example, one or more selected from diluents, flavors, preservatives, excipients, disintegrants, lubricants, binders, surfactants, plasticizers, etc. Can also be used.
- the dose and frequency of administration of the medicament of the present invention are not particularly limited, and the kind, administration route, purpose of treatment and prevention or prevention, the age and weight of the patient, the nature and severity of symptoms of the active ingredient are described above. It can be appropriately selected according to various conditions such as. For example, it is preferable to administer 0.1 to 100 mg / kg per adult daily in 3 to 4 divided doses. However, these dosages and the number of administrations vary depending on the various conditions described above. BEST MODE FOR CARRYING OUT THE INVENTION
- the corresponding fumarate was prepared according to the following method.
- Example 7 Compound 1 4 ⁇ 2_ (2,5-dihydropyro-l-1-1-methyl) -1 8 — (2-ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridine-1 3— Synthesis of 1,11-dihidro-5H-dibenzo [b, f] azepine ⁇
- Reference Example 8 Compound 15 ⁇ N- [8- (2-Ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridin_3-ylmethyl) _10 , 11-Dihydro-5H-dibenzo [b, f] azepine-2-ylmethyl] -1-N-methylamino ⁇ acetic acid methyl ester
- Reference Example 10 Compound 17 2— ⁇ N_ [8— (2-ethyl-5,7-dimethyl-3H-midazo [4,5-b] pyridin-3-ylmethinole) -1 10,11-dihydro-5H-dibenzo [b , F] azepine-12-ylmethyl] —N-methylamino ⁇ ethanol>
- Lithium aluminum hydride (15.7 mg, 0.38 mmol) was suspended in tetrahydrofuran (0.3 mL) and cooled on ice.
- Compound 15 (126 mg, 0.253 mmol) obtained in Reference Example 8 dissolved in tetrahydrofuran (0.9 mL) with stirring under stirring. Was added and stirred at room temperature for 1.5 hours.
- Reference Example 11 1 Compound 1 8- (11- [8- (2-Ethyl-5,7-dimethyl_3H-imidazo [4,5-b] pyridin-3-3-inoremethinole) -1 10,11-Dihydro-5H-dibenzo [ Synthesis of b, f] azepine-2-ylmethyl] pyridine-14-yl ⁇ methanol> Compound 16 was used in the same manner as in Reference Example 10 except that compound 16 was used instead of compound 15 In%, compound 18 was obtained.
- Reference Example 13 Compound 20 ⁇ 1— [8— (2-ethyl-5,7—dimethyl-3H—imidazo [4,5-b] pyridin-1-3-ylmethyl) -1,10,11 Synthesis of —dihydro 5H—dibenzo [b, f] azepine-12-ylmethyl] piperidine-14-force rubonic acid) Compound 16 was used in place of compound 15 in the same manner as in Reference Example 12. Compound 20 was obtained with a yield of 70%.
- Reference Example l 4 Compound 21 ⁇ N- [8- (2-ethyl-5,7-dimethyl-3H-imidazo [ 4,5-b] pyridin-3- (inolemethinole) _ 10,11-dihydro-5H-dibenzo [b, f] azepine-12-ylmethinole] -N-methylamino ⁇ acetonitrinole Synthesis
- 2-methoxypytilamine was used in place of 2- (pyrrolidine-1-yl) ethylamine, and N— [8— ( 2— 1,7-Dimethyl-3H-imidazo [4,5-b] pyridin-13-ylmethyl) -1 10,11-Dihydro 5H-dibenzo [b, f] azepin-2-ylmethyl] -1 N— ( 2-Methoxyxethyl) amine was obtained.
- Compound 23 was obtained as a fumarate in the same manner as in Reference Example 1.
- 2-tritinolone 21 ⁇ ⁇ -tetrazone-1-1-5-innometane-no-nore (2.00 g, 5.84 mmol), N-methino-le-2-2-to-open-mouth benzenesnorrenamide (1.64 g, 7.59) mmol) and triphenylinolephosphine (1.53 g, 5.84 mmol) were dissolved in a mixed solvent of tetrahydrofuran (30 mL) and toluene (20 mL), and a solution of dimethyl diazodicarboxylate (40%, 2.65 mL) was added. , 5.84 mmol) and stirred at room temperature overnight.
- Reference Example 30 Compound 9 9 ⁇ 2-benzyloxymethinolate 8 -— (2-ethyl-5,7) —Dimethinolay 3H—Imidazo [4,5-b] pyridin-3- (ylmethinole) -1-10,11—dihydro_5H—Dibenzo [b, f] azepine ⁇
- Compound 100 was obtained in a yield of 38% in the same manner as in Reference Example 25 using 2-phenylethanol in place of methanol.
- Example 35 Compound 1 0 4 ⁇ 2- (2-Ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridine-1-3-ylmethinole) -1 8— (2H-te 5-yl) Synthesis of 10,11-dihydro 5H-dibenzo [b, f] azepine ⁇
- Reference Example 3 8 Compound 10 7 ⁇ [8- (2-Ethyl_5,7-Dimethyl-3H-imidazo [4,5-b] pyridin-13-ylmethyl) -1 10,11 Dihydro 511-dibenzo [b, f] azepine-12-yl] acetic acid ⁇
- Reference Example 39 Compound 108 [[8- (2-Ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridin-1 3— Synthesis of 10-, 11-dihydro-5H-dibenzo [b, f] azepine-12-inolemethylsnolephanyl] acetic acid methyl ester (lmethyl))
- Compound 13 obtained in Reference Example 6 (1.04 g, 1.71 mmol) was dissolved in chloroform (17 mL), and methylesterenolate mercaptoacetate (0.199 mL, 2.23 mmol) and 1,8-diazavicic mouth [5,4,0] indene (0.384 mL, 2.57 mmol) and stirred at 40 ° C for 7 hours.
- the acetic acid (10,11-dihydro-5H-dibenzo [b, f] azepine-12-ylmethyl) estenole (2.85 g, 10.7 mmol) obtained in Step 1 was suspended in methanol (110 mL), and the sodium methoxide was added. Toxide / methanol solution (38%, 1.14 mL, 5.36 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated, and the residue was added with saturated saline and black form, and extracted three times with black form. Combine the organic layers, The extract was dried over anhydrous magnesium sulfate and concentrated.
- 10,11-Dihydro-5H-dibenzo [b, f] azepine-1-2-force obtained in step 5 was combined with ethinolestaine olevonate (443 mg, 1.66 mmol) in chlorofonolem (8.3 mL) and acetic acid. (8.3 mL), mixed with piperidine (0.573 mL, 5.80 mmol) and paraformaldehyde (149 mg, 4.97 mmol), heated to 60 ° C, and stirred for 1.5 days. The reaction solution was concentrated, ethyl acetate and saturated aqueous sodium hydrogen carbonate were added to the residue, and the mixture was extracted with ethyl acetate.
- the reaction solution was diluted with ethyl acetate, washed sequentially with ice, water, and saturated saline, dried over anhydrous magnesium sulfate, and concentrated.
- the residue was purified by gel chromatography on silica gel (eluent: methanol / form: 1/99), and the fraction containing the target compound was concentrated. Getyl ether was added to the residue, and the mixture was stirred under heating and refluxing conditions for 0.5 hour and then at room temperature for 1 hour. The precipitated crystals were collected by filtration to give Compound 110.
- Reference Example 45 5 Compound 1 1 4 ⁇ [8— (2-ethyl 5,7-Dimethyl-3H-midazo [4,5-b] pyridin-3-ylmethyl-1-10,11-dihydro 5H-dibenzo [b, f] azepine 1-2-yl ] (4-Hydroxypyridino) methanone ⁇
- Reference Example 4 7 Compound 1 16 ⁇ 8- (2-Ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridin-1-ylmethyl)-10 , 11—Dihydro-5H-divenzo [b, f] azepine-12-carburonic acid [2- (pyrrolidine-11-yl) ethyl] amide]
- Reference Example 20 1- [8- (2-Ethyl-5,7-dimethyl-3 ⁇ -imidazo [4,5-b] pyridin-13-ylmethinole) -1 10,11 obtained from Reference Example 10 Using 5H-dibenzo [b, f] azepine-12-ylmethyl] piperidine-14-carbotrile in the same manner as in Step 1 of Reference Example 52, a yield of 92% was obtained.
- Reference Example 54 Compound 1 2 3 ⁇ 1-1-1 [8- (2-ethyl- 5,7-Dimethyl-13H-imidazo [4,5-b] pyridin-3-ylmethinole) -5-methyl-10,11-dihydro-5H-dibenzo [b, f] azepine-1 Synthesis of pyrimidine] piperidine
- Reference Example 5 7 Compound 9 1 ⁇ 1,4-bis [4- (3- Benzylamino) -6-cyclopropylcarbonyl_7,8-dihydro-5H-pyrido [4,3-d] pyrimidin-2-yl] pyrazine ⁇
- the compound (F) (5.0 g, 13.3 mmol) obtained in Step 5 was dissolved in dioxane (100 mL), and tert-butyl-1-piperazinecarboxylate (4.9 g> 2 equivalents) and sodium carbonate (14.0 g , 10 equivalents) and stirred at 90 ° C for 3 days.
- the obtained reaction solution was filtered to remove sodium carbonate, and the filtrate was extracted with water and quenched form, and the organic layer was dried over magnesium sulfate. After evaporating the solvent, a mixed solvent of hexane / ethyl acetate (3: 1) was added to the residue, and the suspension was stirred for 1 hour. Thereafter, the precipitated crystals were collected by filtration and dried under reduced pressure to obtain Compound (G) (6.4 g, yield 92%).
- Gal4-ER chimera gene [Cellen, Vol. 54, p. 199 (1988), Proc. I. Dender's Op. The National. Academy. Op. Science 'Ob' The Unites de St. Op. Acer (Proc. Natl. Acad. Sci. USA), vol. 90, p. 1657 (1993)] containing ER a AF2 in pM (distributed by Shigeaki Kato of the University of Tokyo) by Aatll and Ndel. After cleavage, the fragment was treated with Klenow to obtain an Aatll (blunt end) -Ndel (blunt end) fragment.
- Plasmids were ligated by joining the (blunt-end) _g £ _RI (blunt-end) fragment from pSV2bsr and the ⁇ 11 (blunt-end) -Ndel (blunt-end) fragment from ERo; AF2 in pM described above.
- pGERbsrR2 was constructed.
- pGERbsrR2 is a yeast
- Gal4-ER chimeric protein
- pAMoERC3Sc Japanese Unexamined Patent Publication No. 05-336963 was digested with Xhol and Nsil, followed by Klenow treatment to obtain a 2.2 kb 3 ⁇ 41 (blunt end) (blunt end) fragment containing the oriP sequence.
- plasmid pcDNA3-oriP was constructed.
- pcDNA3-oriP was cut with Xhol and Hindlll to obtain Xhol-Hindlll fragment.
- pSE01uc2 (W098 / 14474) was digested with Xhol and Ncol, and treated with Klenow to obtain a ⁇ I (blunt end) -Ncol (blunt end) fragment containing the ampicillin resistance gene. By ligating the fragments, a plasmid pASdl-lucl was constructed. After cutting pASdl-lucl with Xhol and Hindlll, a 0.1 kb Xhol-Hindlll fragment was obtained.
- the Xhol-Hindlll fragment derived from pcDNA3-oriP and the Xhol-Hindlll fragment derived from pASdl-lucl were ligated to form plasmid pcDNA3-oriP-Sdl.
- pcDNA3-oriP-Sdl was digested with Xhol and Kpnl to obtain an Xhol-Kpnl fragment.
- Four types of DNAs having the nucleotide sequences represented by SEQ ID NOs: 1, 2, 3, and 4 were synthesized using a DNA synthesizer. The synthetic DNA is mixed and annealed to form a double-stranded DNA having a poly-A-added signal. Each of the synthetic DNAs was
- Plasmid pcDNA3-oriP-Sdl-pA was constructed by binding the double-stranded DNA to an Xhol-Kpnl fragment derived from pcDNA3-oriP-Sdl.
- pcDNA3-oriP-Sdl One pA was cut with ⁇ I, and then treated with Klenow to obtain a 1 (blunt end) fragment.
- pFR-luc manufactured by Stratagene
- was digested with Hindlll and BamHI it was treated with Klenow to obtain a 0.14 kb iil ⁇ dlll (blunt-ended) ⁇ HI (blunt-ended) fragment.
- pAGalSdl contains a promoter having a sequence obtained by repeating Gal4p response element (UASG) five times. After pAGalSdl was digested with EcoRI, it was treated with Klenow to obtain an EcoRI (blunt end) fragment.
- pSE01uc2 (098/14474) was digested with Hindlll and Sacl and treated with Klenow to obtain a 1.7 kb Hindlll (blunt end) — ⁇ 1 (blunt end) fragment containing the firefly luciferase gene.
- Plasmid pAGalSd to luc was constructed by combining the above-mentioned iLdlll (blunt-end) 1 ⁇ I (blunt-end) fragment derived from pSE01uc2 and the ⁇ RI (blunt-ended) fragment derived from pAGalSdl.
- Virus oriP was cleaved with Hindlll and Sacl, was acquired with Hindlll- Sacl fragment of 6.9kb including oriP.
- pAMo-d a JP 2001-211885) was digested with Hindlll and Sacl, were obtained HindIII_SacI fragment containing the tetracycline resistance gene (Tc R).
- Hindlll -Sacl fragment Hindlll- Sacl fragments, and origin pAMo-d from the above P AGal9-luc plasmid the firefly 'Rushifu Eraze gene portion in pAGal9_luc replaced with Stuffer sequences pAMo-d P AGal9_d was created.
- pAGa! 9-luc was digested with Hindlll and Sacl to obtain a Hindlll -Sacl fragment of 6.9 kb.
- Hindlll-Sacl fragment derived from pAGal9-luc and pAMo-nd Hindlll- by combining Sacl fragment, pAGAL 9 - firefly Rushifu Weraze gene portion in luc was constructed a plasmid pAGal9-nd was replaced with Stuffer sequences pAMo-nd.
- Namalwa KJM-1 cells are serum-free adapted B cell lines that express the EBNA-1 gene.
- the transformant cells the RPMI1640.ITPSG medium [RPMI1640 medium 8 ml (Nissui Pharmaceutical), 1/40 volume of 7.5 0/0 NaHC0 3, 3 % 200mmol / LL- Gunoretamin soluble ⁇ night (a down-bi 0.5% penicillin. Streptomycin solution (Invitrogen, 5,000 units / ml penicillin, 5,000 g / ml streptomycin), 10ramol / L N_2-H Droxityl piperazine- ⁇ '- 2-ethanesulfonic acid
- Induced expression plasmid of firefly luciferase in each transformant pAGalSdl-luc was introduced by an electroporation method and cultured for 2 days. After the culture, estradiol (ESS 75 : manufactured by Sigma) (final concentration: lOnmol / L) was added, and after further culturing for 24 hours, the firefly luciferase activity was measured.
- estradiol ESS 75 : manufactured by Sigma
- a substrate solution [25 mmol / L Guji Shinoreguji Shin (pH7.8), 15 mmol / L MgS0 4, 5
- pACREpluc a reporter plasmid capable of expressing the firefly luciferase gene under the control of the cAMP response element (CRE), was constructed by the following method.
- pACREpluc has a hygromycin resistance gene and an oriP of Epstein's B. inores.
- a Clal-Mlul fragment was obtained.
- the ClaI- ⁇ fragment derived from pAMo and the Clal-Mlul fragment derived from pAGE248 were ligated to construct a plasmid pAMoh.
- ⁇ I-I Hindlll fragment containing the hygromycin resistance gene was obtained.
- pAGal9-luc was cut with Sail and Hindlll to obtain a Sail-Hindlll fragment containing oriP and Gal4UAS.
- Plasmid pAGal9h was constructed by combining the Sail-Hindlll fragment derived from pAGal9-luc and the Xhol-Hindlll fragment derived from pAMoh described above.
- pBluescriptll KS + (manufactured by Toyobo Co., Ltd.) is cleaved with Sail and Xhol, followed by dephosphorylation using phosphatase (Alkaline Phosphatase E. coli C75, manufactured by Takara Shuzo), and a Sail-Xhol fragment containing the ampicillin resistance gene was obtained.
- a double-stranded DNA containing two CRE sequences was prepared by annealing synthetic oligonucleotides having the nucleotide sequences represented by SEQ ID NOS: 5 and 6.
- pBS-CREI is a plasmid in which the double-stranded DNA is integrated in a direction in which the ⁇ ⁇ 11 cleavage site and the ⁇ I cleavage site are regenerated, and each has one of the above-mentioned cleavage sites.
- Seal-Xhol fragment was obtained.
- pBS-CREI was cut with Seal and Sail to obtain a Seal-Sail fragment containing ColEl ori.
- the pBS-CREI-derived Seat Xhol fragment and the Seat Sail fragment were ligated to construct pBS-CREII containing four CRE sequences.
- Scal-Xhol fragment was obtained.
- pBS-CREII was cut with Seal and Sail to obtain a Sea Sail fragment containing ColEl ori.
- the pBS-CREII-derived Seat Xhol fragment and Seal-Sail fragment were ligated to construct pBS-CREIV containing eight CRE sequences. Cleavage pBS-CREIV with Seal and Xhol, containing ori of phage ⁇
- Seal-Xhol fragment was obtained.
- pBS- was cleaved with Seal and Sail to obtain a Seal-Sail fragment containing ColEl ori.
- the pBS-CREIV-derived Seat Xhol fragment and the Seal-Sail fragment were ligated to construct pBS-CREVIII containing 16 CRE sequences.
- the pBS-CREVIII was digested with Xhol, treated with Klenow, and digested with Hindlll to obtain a ⁇ dlll-1 (blunt-ended) fragment containing 16 CREs.
- pAGalSdl was cut with Mlul and Hindlll to obtain a 1. kb Mlul-Hindlll fragment.
- pAGal9-luc was digested with Xhol and otl to obtain an Xhol-Notl fragment containing the firefly luciferase gene.
- pACREh was cut with Xhol and otl to contain the CRE sequence — a Notl fragment was obtained.
- Plasmid pACREluc was constructed by joining the Xhol-Notl fragment derived from pAGal9-luc and the Xhol-Notl fragment derived from pACREh.
- pACREluc is digested with Hindlll, treated with Klenow, and further digested with Xhol, so that Hindlll (blunt end) -Xhol fragment containing CRE and iii ⁇ dlll (blunt end) I ⁇ I fragment containing firefly luciferase gene Were obtained.
- Hindlll (blunt end) -Xhol fragments derived from pACREluc a plasmid pACRElucH in which the ndlll site upstream of the CRE sequence in pACREluc had disappeared was constructed.
- the pGL3-Enhancer vector (Promega) was cut with Hindlll and Hpal to obtain a Hindlll-Hpal fragment containing the luc + gene (modified firefly luciferase gene).
- pACRElucH was cut with otl, treated with Klenow, and further cut with Hindlll to obtain a Hindi II-Notl (blunt end) fragment containing CRE.
- a plasmid pACREpluc was constructed by ligating a Hindlll-Hpal fragment derived from the pGL3-Enhancer vector and a Hindlll-Notl (blunt end) fragment derived from pACRElucH.
- Reference Example 60 Construction of GPR4-induced expression plasmid
- Single-stranded cDNA was synthesized by the First-Strand Synthesis System for RT-PCR (manufactured by Gipco). Using a solution 5/1 obtained by diluting the single-stranded cDNA O-fold with water as type III, and using a synthetic DNA having the sequence shown in SEQ ID NOs: 7 and 8 as a GPR4 gene-specific primer, PCR was performed. As a result, GPR4 cDNA was obtained.
- the sequence of the GPR4 gene-specific primer is based on the sequence information of the GPR4 gene (GenBatik accession number: U21051). Designed.
- PfuTurbo DNA Polymerase (Stratagene) was used.
- a 10-fold concentration buffer added to the enzyme to be used was used as a buffer for performing PCR.
- PCR was performed using a thermal cycler DNA engine (manufactured by MJ Research) at 95 ° C for 5 minutes, followed by a reaction consisting of 94 ° C for 1 minute, 60 ° C for 1 minute, and 72 ° C for 1 minute. Was performed by performing 30 cycles.
- the amplified GPR4 cDNA fragment was cut with Hindlll and NotI, which cut the sequence designed on the primer.
- the fragment containing GPR4 cDNA was recovered by agarose gel electrophoresis.
- GPR4-induced expression plasmid pAGal9-GPR4 was constructed by incorporating the cleaved fragment into Hindlll-NotI of plasmid pAGal9-nd.
- nucleotide sequence was determined using a DNA Sequencer 377 from Perkin-Elma and a reaction kit (ABI Prism TM BigDye TM Terminator Cycle Sequencing Ready Reaction Kit: Applied Biosystems).
- GPR4-induced expression plasmid pAGal9-GPR4 (2 ⁇ g) and reporter plasmid KpACREpluc (2 ⁇ g) were co-transfected into KJMGER8 of 6 ⁇ 10 6 cells by the above electroporation method.
- Nigoshi Suspend the transformant strain RPMI1640'ITPSG medium 8 ml, in C0 2 incubator primary, cultured for 24 hours at 37 ° C. After cultivation, add plasticidin S (2.0 ⁇ g / ml), hygromycin B (300/2 g / ml) and dieneticin (500 g / ml), and further cultivate for 14 days. (Referred to as GPR4 Atsushi cells).
- the transformant was transformed with plasticidin S (2.0 ⁇ g / ml), hygromycin ⁇ (300 ⁇ g / ml) and dieteticin (500 ⁇ g / ml). ( ⁇ g / ml) in RPMI1640-ITPSG medium.
- control plasmid pAGal9-nd (2 ⁇ g) and reporter plasmid pACREpluc (2 Atg) were co-transfected into KJMGER8 to obtain a stable transformant (referred to as a control cell).
- Reference Example 62 Cloning of DNA encoding human GPR4 homolog from mouse
- polypeptide having the amino acid sequence represented by SEQ ID NO: 13 was a mouse human GPR4 homolog (mouse GPR4).
- the DNA encoding mouse GPR4 is an oligonucleotide that can be designed and synthesized based on the nucleotide sequence represented by SEQ ID NO: 14, using a mouse cDNA library that can be prepared for sale or by a known method, as type III. Can be obtained by PCR used for the primer set.
- thermal cycler PTO200 manufactured by MJ Research
- heat at 95 ° C for 10 minutes, and then process at 94 ° C for 1 minute, 55 ° C for 1 minute, and 72 ° C for 1 minute as one cycle. After 30 cycles, the mixture was further heated at 72 ° C for 5 minutes.
- Plasmid pT7RG was obtained by a conventional method from a transformant obtained by transforming Escherichia coli JM109 strain using the obtained recombinant plasmid DNA. As a result of determining the entire nucleotide sequence of plasmid pT7RG, it was found that PT7RG contained a cDNA of about 1.1 kb having the nucleotide sequence represented by SEQ ID NO: 18.
- SEQ ID NO: 17 shows the amino acid sequence of the polypeptide encoded by the DNA consisting of the nucleotide sequence represented by SEQ ID NO: 18.
- the amino acid sequence of human and mouse GPR4 was compared with the amino acid sequence of human and mouse GPR4 using an analysis program [GENETYX f IN ver. 5.0 (manufactured by Softea)] to find that the amino acid sequence was 93.0% and 99.2%, respectively. A% match was found.
- Example 1 Tablet A tablet having the following composition is prepared by a conventional method. Formulation Compound 1 20 mg
- a prophylactic and / or therapeutic agent for asthma containing, as an active ingredient, a substance that inhibits the function related to GPR4 signal transduction, and a nitrogen-containing tricyclic compound or a quaternary ammonium salt thereof or
- the present invention provides a prophylactic and / or therapeutic agent for asthma containing such a pharmacologically acceptable salt as an active ingredient.
- SEQ ID NO: 2 Description of artificial sequence: synthetic DNA SEQ ID No. 3—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 4—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 5—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 6—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 7—Artificial Sequence Description: Synthetic DNA SEQ ID No. 8—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 9—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 10—Description of Artificial Sequence: Synthetic DNA SEQ ID No. 15—Description of Artificial Sequence: Synthetic DNA SEQ ID NO: 16—Description of Artificial Sequence: Synthetic DNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003262229A AU2003262229A1 (en) | 2002-08-22 | 2003-08-22 | Preventive and/or therapeutic drugs for asthma |
JP2004530440A JPWO2004017994A1 (ja) | 2002-08-22 | 2003-08-22 | 喘息の予防および/または治療剤 |
EP03792561A EP1537879A4 (en) | 2002-08-22 | 2003-08-22 | PREVENTIVE AND / OR THERAPEUTIC DRUGS AGAINST ASTHMA |
US10/525,326 US20060239999A1 (en) | 2002-08-22 | 2003-08-22 | Preventive and/or therapeutic drugs for asthma |
CA002496573A CA2496573A1 (en) | 2002-08-22 | 2003-08-22 | Agent for prevention and/or treatment of asthma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-241523 | 2002-08-22 | ||
JP2002241523 | 2002-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004017994A1 true WO2004017994A1 (ja) | 2004-03-04 |
Family
ID=31943996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/003470 WO2004017994A1 (ja) | 2002-08-22 | 2003-08-22 | 喘息の予防および/または治療剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060239999A1 (ja) |
EP (1) | EP1537879A4 (ja) |
JP (1) | JPWO2004017994A1 (ja) |
AU (1) | AU2003262229A1 (ja) |
CA (1) | CA2496573A1 (ja) |
WO (1) | WO2004017994A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093912A1 (ja) * | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | 好中球性炎症疾患の予防および/または治療剤 |
US7250417B2 (en) | 2003-07-02 | 2007-07-31 | Sugen Inc. | Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors |
WO2008096829A1 (ja) | 2007-02-07 | 2008-08-14 | Kyowa Hakko Kirin Co., Ltd. | 3環系化合物 |
JP4866723B2 (ja) * | 2004-02-26 | 2012-02-01 | 協和発酵キリン株式会社 | 好中球性炎症疾患の予防及び/または治療剤 |
US8486980B2 (en) | 2008-08-06 | 2013-07-16 | Kyowa Hakko Kirin Co., Ltd. | Tricyclic compound |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1885369B1 (en) * | 2005-05-04 | 2015-09-23 | Evotec AG | Fused heterocyclic compounds, and compositions and uses thereof |
WO2007023880A1 (ja) * | 2005-08-24 | 2007-03-01 | Kyowa Hakko Kogyo Co., Ltd. | ケモカイン産生阻害剤 |
WO2010145696A1 (en) * | 2009-06-16 | 2010-12-23 | Martin Jan Peter Eversdijk | Methods for detecting the presence or absence of blood |
US8748435B2 (en) | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
CN113999810B (zh) * | 2021-12-30 | 2022-04-26 | 北京赛尔富森生物科技有限公司 | 一种mrc-5细胞复苏培养液以及复苏方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325755A1 (en) * | 1987-12-14 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
EP0549352A2 (en) * | 1991-12-27 | 1993-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as angiotensin II antagonists |
JPH0940662A (ja) * | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
WO2000022129A1 (en) * | 1998-10-13 | 2000-04-20 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human g protein-coupled receptors |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK60593D0 (da) * | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
US6221627B1 (en) * | 1997-02-24 | 2001-04-24 | Smithkline Beecham Corporation | cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor |
US7105488B1 (en) * | 1998-02-27 | 2006-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | G protein-coupled receptor antagonists |
-
2003
- 2003-08-22 AU AU2003262229A patent/AU2003262229A1/en not_active Abandoned
- 2003-08-22 CA CA002496573A patent/CA2496573A1/en not_active Abandoned
- 2003-08-22 WO PCT/IB2003/003470 patent/WO2004017994A1/ja not_active Application Discontinuation
- 2003-08-22 US US10/525,326 patent/US20060239999A1/en not_active Abandoned
- 2003-08-22 EP EP03792561A patent/EP1537879A4/en not_active Withdrawn
- 2003-08-22 JP JP2004530440A patent/JPWO2004017994A1/ja not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325755A1 (en) * | 1987-12-14 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
EP0549352A2 (en) * | 1991-12-27 | 1993-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as angiotensin II antagonists |
JPH0940662A (ja) * | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
WO2000022129A1 (en) * | 1998-10-13 | 2000-04-20 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human g protein-coupled receptors |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
Non-Patent Citations (5)
Title |
---|
HEIBER, M: "Isolation of Three Novel Human Encoding G Protein-Coupled Receptors", DNA CELL BIOL., vol. 14, no. 1, 1995, pages 25 - 35, XP002066093 * |
MAHADEVAN, M.S.: "Isolation of a Novel G Protein-Coupled Receptor (GPR4) Localized to Chromosome 19q13.3.", GENOMICS, vol. 30, 1995, pages 84 - 88, XP002920408 * |
NISHIYA, Y AND SUGIMOTO, S: "Effects of Various Antihypertensive Drugs on the Function of Osteoblast.", BIOL. PHARM. BULL, vol. 24, no. 6, 2001, pages 628 - 633, XP002974916 * |
See also references of EP1537879A4 * |
ZHU, K ET AL: "Sphingosylphosphorylcholine and Lysophosphatidylcholine are ligands for the G Protein-coupled Receptor GPR4", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 44, 2 November 2001 (2001-11-02), pages 41325 - 41335, XP002974915 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004093912A1 (ja) * | 2003-04-23 | 2004-11-04 | Kyowa Hakko Kogyo Co. Ltd. | 好中球性炎症疾患の予防および/または治療剤 |
US7250417B2 (en) | 2003-07-02 | 2007-07-31 | Sugen Inc. | Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors |
JP4866723B2 (ja) * | 2004-02-26 | 2012-02-01 | 協和発酵キリン株式会社 | 好中球性炎症疾患の予防及び/または治療剤 |
WO2008096829A1 (ja) | 2007-02-07 | 2008-08-14 | Kyowa Hakko Kirin Co., Ltd. | 3環系化合物 |
US8242151B2 (en) | 2007-02-07 | 2012-08-14 | Kyowa Hakko Kirin Co., Ltd. | Tricyclic compounds |
US8486980B2 (en) | 2008-08-06 | 2013-07-16 | Kyowa Hakko Kirin Co., Ltd. | Tricyclic compound |
US9475805B2 (en) | 2008-08-06 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | Tricyclic compound |
Also Published As
Publication number | Publication date |
---|---|
AU2003262229A1 (en) | 2004-03-11 |
JPWO2004017994A1 (ja) | 2005-12-08 |
US20060239999A1 (en) | 2006-10-26 |
CA2496573A1 (en) | 2004-03-04 |
EP1537879A1 (en) | 2005-06-08 |
EP1537879A4 (en) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10183951B2 (en) | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | |
JP6876685B2 (ja) | Atx阻害剤としての二環式化合物 | |
TWI330180B (en) | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | |
JP6553637B2 (ja) | オートタキシン(atx)及びリゾホスファチジン酸(lpa)生成阻害剤としての二環式化合物 | |
JP4286134B2 (ja) | ベンズイミダゾ[4,5−f]イソキノリノン誘導体 | |
JP6846414B2 (ja) | Atx阻害剤としての二環式化合物 | |
CN104364239B (zh) | 二氮杂螺环烷烃和氮杂螺环烷烃 | |
TWI360541B (en) | Novel compounds | |
JP2019031537A (ja) | エストロゲン受容体調節剤としての6,7−ジヒドロ−5h−ベンゾ[7]アヌレン誘導体 | |
CN110511219B (zh) | 苯基取代的二氢萘啶类化合物及其用途 | |
TW201425300A (zh) | 用以合成甲狀腺激素類似物及其多形體之方法 | |
WO2007055418A1 (ja) | アザ置換スピロ誘導体 | |
HU229025B1 (en) | Pyrazole derivatives for treating hiv, pharmaceutical compositions containing them and process for their preparation | |
TW201605861A (zh) | 新穎的八氫-環四[1,2-c;3,4-c’]二吡咯-2-基 | |
JP2001505873A (ja) | Hiv逆転写酵素阻害剤として有用な4,4―二置換―1,4―ジヒドロ―2h―3,1―ベンゾオキサジン―2―オン類、およびそれらを製造するための中間体および方法 | |
US7300943B2 (en) | GSK-3 inhibitors | |
WO2004093912A1 (ja) | 好中球性炎症疾患の予防および/または治療剤 | |
RU2765718C1 (ru) | Замещенное производное дигидропирролопиразола | |
TW200526625A (en) | Pharmaceutically active compounds | |
BRPI0708264A2 (pt) | piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina | |
WO2008056687A1 (fr) | Nouveau dérivé de spiropipéridine | |
JPWO2004054617A1 (ja) | 中枢疾患の予防および/または治療剤 | |
JP7397452B2 (ja) | ヘテロアリールカルボキシアミド化合物 | |
WO2004017994A1 (ja) | 喘息の予防および/または治療剤 | |
WO2004017995A1 (ja) | 掻痒の予防および/または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004530440 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2496573 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006239999 Country of ref document: US Ref document number: 10525326 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003792561 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003792561 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10525326 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003792561 Country of ref document: EP |